TAIKO PHARMACEUTICAL CO., LTD. (4574) Income statement

Market cap

¥15.4B

P/E ratio

27.8x

Makes over-the-counter medicines like Seirogan and Cleverin infection control products, serving consumers and institutions across Japan and Asia.

Summary Financials Dividends History Ownership Workforce

Income statement Balance sheet Cash flow Other

	2012/03	2013/03	2014/03	2015/03	2016/03	2017/03	2018/03	2019/03	2020/03	2020/12	2021/12	2022/12	2023/12	2024/12	2025/12
Revenue	6,684	7,444	9,947	8,979	8,327	8,295	9,459	10,419	14,966	17,583	11,299	5,040	6,120	6,292	6,397
Revenue growth (%)	-
Cost of revenue	-	-	-	2,355	2,556	2,714	2,886	3,216	4,358	5,263	7,973	3,961	3,543	2,626	2,916
Gross profit	-	-	-	6,624	5,771	5,581	6,573	7,203	10,608	12,320	3,325	1,078	2,577	3,666	3,481
Gross margin (%)	-	-	-
Operating margin (%)	-	-	-
Operating expenses	-	-	-	4,324	4,391	4,025	4,695	5,132	6,754	6,770	7,694	4,157	3,583	3,036	3,022
Operating income	-	-	-	2,559	1,348	1,545	1,857	2,030	3,825	5,651	-4,947	-3,079	-1,005	629	459
Income before tax	559	1,212	2,684	2,776	1,307	1,408	1,568	1,885	3,633	5,454	-6,131	-3,352	-1,248	688	482
Pretax margin (%)	8.4	16.3	27	30.9	15.7	17	16.6	18.1	24.3	31	-54.3	-66.5	-20.4	10.9	7.5
Provision for income taxes	-	-	-	988	351	442	458	570	1,051	1,523	706	25	47	-332	34
Effective tax rate (%)	-	-	-
Net income	373	899	1,536	1,771	840	1,049	1,095	1,415	2,453	3,852	-9,594	-4,895	-3,611	898	923
Earnings per share	37.23	81.31	135.94	138.93	65.23	76.45	77.38	98.99	57.57	89.18	-220.52	-112.26	-76.25	17.9	18.38
Diluted EPS	36.51	80.09	131.56	134.47	63.83	75.81	77.06	98.88	57.34	88.82	-	-	-	-	-
Dividend payout ratio (%)	-	-	-	-	-	-	-	-			-	-	-	-	-
Dividend per share	-	-	-	-	-	-	-	-	50	25	-	-	-	-	3.3